Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07123649 · ClinicalTrials.gov registry record · Phase 2

Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study

A Phase 2 study of Breast Cancer, sponsored by Dana-Farber Cancer Institute.

Recruiting
Registry status
Phase 2
Development phase
364
Enrollment target
1
Study location

NCT07123649: Recruiting Phase 2 study of Breast Cancer, sponsored by Dana-Farber Cancer Institute.

NCT07123649 is a Phase 2 study of Breast Cancer that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 364 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07123649, a Phase 2 study of Breast Cancer, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.

RECRUITING
Registry status
Phase 2
Development phase
364 participants
Enrollment target
1
Study location

Study Summary

This study evaluates the effectiveness of a Shared Decision-Making (SDM) toolkit designed to support older breast cancer survivors aged 80 and above in making informed decisions about continuing surveillance mammography.

Primary Outcome

Mammography Rate is defined as the proportion of participants that undergo mammography by 2 years post-enrollment.

Conditions Studied

Interventions

  • BEHAVIORAL Shared Decision-Making Toolkit

Study Locations (1)

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 364 participants
Start Date 2026-02
Est. Completion 2029-09-30
Phase Phase 2
Dana-Farber Cancer Institute

781 total trials

What NCT07123649 shows while recruiting

NCT07123649 is an interventional study that assigns participants to a tested intervention. The registered 364 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Shared Decision-Making Toolkit is the first listed.

NCT07123649 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07123649 about?

NCT07123649 is a clinical study titled "Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study". This study evaluates the effectiveness of a Shared Decision-Making (SDM) toolkit designed to support older breast cancer survivors aged 80 and above in making informed decisions about continuing surveillance mammography.

What is the current status of trial NCT07123649?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 364 participants. The study started on 2026-02. Estimated completion is 2029-09-30.

What conditions does trial NCT07123649 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT07123649?

The interventions under investigation include: Shared Decision-Making Toolkit (BEHAVIORAL).

Who is sponsoring clinical trial NCT07123649?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07123649 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07123649's enrollment target sits among peer trials

364 252nd of 1224 higher than 973 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04510597 · 364 participants · Phase 3

    Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

  • NCT05098132 · 364 participants · Phase 1

    Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

  • NCT05330221 · 364 participants · NA

    Project 2: ACHIEVE- HF

  • NCT05673148 · 364 participants · Phase 3

    Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT07123649, the US trial registry maintained by the National Library of Medicine. NCT07123649 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.